The need to restore normal blood flow to prevent tissue injury from oxygen deprivation is a common theme in acute clinical settings that involve ischemia. While restoration of blood flow in this setting is critical, reperfusion may further augment tissue damage (1). Reperfusion injury is characterized by the release of free radicals, microvascular dysfunction, and infiltration of immune cells and inflammatory mediators, resulting in further damage to both local and/or remote tissues (2, 3).
The complement system is a well-accepted mediator of inflammation and ischemia/reperfusion (I/R) injury and exerts its effects in a number of ways (4, 5). For example, complement activation leads to the release of proinflammatory anaphylatoxins (C3a and C5a) and the tissue-injurious terminal membrane attack complement complex C5b-9. In the context of complement activation, C5a seems to be especially important, because C5a can induce neutrophil attraction and aggregation, chemotaxis, cytotoxic activity, and the release of reactive oxygen metabolites and proteases. In addition, C5a is a potent chemotactic factor for eosinophils, basophils, monocytes/macrophages, and microglial cells and is responsible for the upregulation of vascular adhesion molecules. The biological activity of C5a is mediated by the interaction with its receptor C5aR that is widely expressed in both inflammatory and noninflammatory cells (6).
The role of C5 downstream pathway in preclinical models of intestinal, hepatic, and renal I/R injury has been evaluated using C5-deficient mice and antagonists of C5 and C5aR (7-11). Inhibition of C5 activation by an anti-C5 antibody administered to wild-type (WT) mice subjected to mesenteric I/R prevented C5a generation, polymorphonuclear cell infiltration, and deposition of the terminal complement complex on damaged tissues in a manner similar to that observed in C5-deficient mice (12-16). These studies, however, did not distinguish between the actions of C5a and the C5b-9 terminal complex. Using a pharmacological approach, Fleming et al. (9) attempted to distinguish the actions of C5a and C5b-9 terminal complex by using a C5aR antagonist in WT mice subjected to mesenteric I/R injury. In their study, when C5aR antagonist was administered 5 min before reperfusion, the intestinal damage decreased significantly compared with WT mice subjected to I/R injury without the antagonist; however, the C5aR antagonist did not completely prevent I/R-induced injury. Furthermore, neutrophil infiltration in the intestine and remote organs was not examined.
Consequently, to further study the role of neutrophil infiltration in intestinal I/R injury and its regulation by C5aR, we used a genetic approach using C5aR knockout (KO) mice. In previous studies, these mice have been used to demonstrate the requirement of C5aR for host defense and the synergistic role it plays with its ligand (C5a) and other inflammatory mediators such as TNF-α and IL-6 in immune complex-mediated peritonitis and skin injury (17, 18).
The present study is the first to evaluate C5aR KO mice subjected to I/R injury. In this study, we adopted the superior mesenteric artery occlusion (SMAO) model, which is considered to be a golden "proof of concept" model for I/R injury (19) and conducted a comparison between WT and C5aR KO mice to evaluate the role of C5aR-mediated pathway, using key disease markers such as mucosal damage, neutrophil infiltration to local and remote organs, circulating cytokine levels, and apoptotic cell death.
MATERIALS AND METHODS
The heterozygous C5aR KO mice [strain C.129S4(B6)-C5ar1tm1Cge/J] were licensed from the Children's Hospital Boston and purchased from the Jackson Laboratory (Bar Harbor, Maine). The heterozygous mice were intercrossed to generate homozygous KO mice. The correct homozygous (C5aR−/−) pups were identified by polymerase chain reaction (PCR) genotyping according to the protocol from the Jackson Laboratory. The C57BL/6 mice were used as WT control and were also purchased from the Jackson Laboratory. Male homozygous KO and WT mice aged between 12 and 14 weeks were used for the in vivo study. Animal study protocols were approved by the New Jersey Medical School Animal Care and Use Committee and the Novo Nordisk Ethic Review Committee. The experiments were performed in adherence to the National Institutes of Health Guidelines on the Use of Laboratory Animals.
Intestinal I/R injury model
The model for SMAO was used as previously described (20) and is briefly summarized as follows. Mice were anesthetized intraperitoneally with pentobarbital (70 mg/kg). Through a midline laparotomy, the superior mesenteric artery (SMA) was isolated and temporarily occluded by placing a 4-0 suture around the SMA at its origin from the aorta. An immediate blanching of the small intestine and the cecum confirmed that the blood supply to these intestinal segments was completely shut off. The abdomen was then covered with a sterile moist gauze pad. After 45 min of intestinal ischemia, the ligature was removed around the SMA. After verifying return of blood supply to the intestine, the laparotomy incision was closed. There are four groups of animals: (i) C5aR KO-SMAO: C5aR KO mice subjected to SMAO procedure; (ii) WT-SMAO: WT mice subjected to SMAO procedure; (iii) C5aR KO-sham; and (iv) WT-sham. The mice subjected to sham SMAO were anesthetized and were performed a 3-cm laparotomy, and their SMA was looped with a 4-0 ligature; however, the artery was not occluded. Three hours after reperfusion, sham or SMAO mice were sacrificed, and the tissue was harvested. Whole blood was collected through a cardiac puncture in the syringe containing 0.1 mL of 100 U/mL heparinized saline at sacrifice, and then the blood was centrifuged at 1,500 revolutions per min for 15 min, and the resulted plasma was stored at −80°C.
At sacrifice, a segment of the terminal ileum (1 cm) was excised and fixed in 10% buffered formalin. Semi-thin (4 μm) sections were then cut and stained with hematoxylin-eosin. Five random fields with 100 to 250 villi from each animal were then scored for injury in a blinded fashion using light microscopy at 100× magnification (21).
A 15-cm piece of intestine was taken from the mice and weighed for wet weight after brief cleaning, and then the intestine was placed at 60°C for 48 h and weighed again for dry weight. The ratio is expressed as wet weight divided by dry weight.
Myeloperoxidase activity in tissue homogenates
Three centimeters of ileum was taken by direct snap-freezing in liquid nitrogen for 5 min and then stored at −80°C. In addition, whole lung and a piece of liver tissue were taken and prepared in a similar way. Neutrophil sequestration was quantitated by myeloperoxidase (MPO) activity (22). Myeloperoxidase is considered a biochemical marker for neutrophils as neutrophils contain 5% MPO in total protein. Briefly, the tissue samples (40-50 mg) were homogenized for 30 s in 1 mL of 20 mM potassium phosphate buffer (pH 7.4) and centrifuged for 30 min at 40,000 g at 4°C. The pellet was resuspended in 1 mL of 50 mM potassium phosphate buffer (pH 6) containing 0.5 g/dL hexadecyltrimethyl ammonium bromide. Samples were sonicated for 90 s, incubated at 60°C for 2 h, and then centrifuged. A supernatant sample (100 μL) was added to 2.9 mL of 50 mM potassium phosphate buffer (pH 6), containing 0.167 mg/mL O-dianisidine and 0.0005% hydrogen peroxide. Absorbance at 460 nm (A460) was measured for 3 min.
Apoptotic cell death
Tissue apoptotic cell death was examined using the ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon International, Temecula, Calif). Formalin-fixed paraffin-embedded tissue sections were deparaffinized with xylene followed by absolute ethanol, 95% ethanol, and 70% ethanol. The sections were washed with phosphate-buffered saline (PBS; 5 min) before treatment with protease K (20 μg/mL) for 15 min. After two washes with dH2O for 2 min each, sections were quenched in 3.0% hydrogen peroxidase in PBS for 5 min at room temperature and rinsed twice with PBS for 5 min each time. Equilibration buffer was immediately applied directly to the sections for 20 s at room temperature. Terminal deoxynucleotidyl transferase enzyme was pipetted onto the sections followed by incubation in a humidified chamber for 1 h at 37°C. Slides were placed in a Coplin jar containing working strength stop/wash buffer and incubated for 10 min at room temperature. After rinsing three times in PBS, the sections were incubated with antidigoxigenin conjugate in a humidified chamber for 30 min at room temperature. The sections were rinsed with PBS, and color was developed in peroxidase substrate (AEC Substrate Kit; BD Biosciences Pharmingen, San Diego, Calif). Sections were rinsed in dH2O and counterstained with hematoxylin (Sigma, St Louis, Mo). The specimens were dehydrated and mounted under a glass coverslip. Samples were then examined with bright field microscopy.
Plasma levels of cytokines
Detection of plasma cytokine levels was conducted with the Bio-Plex System (Bio-Rad Laboratories, Hercules, Calif) following the manufacturer's instruction, and the data analysis was performed with the Bio-Plex Manager software. All assays were carried out in a 96-well sterile filter plate (Cytokine Reagent Kit, Bio-Rad Laboratories) at room temperature and protected from light. Mouse cytokine customized three-plex panel (TNF-α, IL-6, and IL-1β) and all reagents were purchased from Bio-Rad Laboratories. Standard curves were always generated before sample determinations. The plasma samples were diluted 4-fold with serum sample diluent. Each sample was determined in duplication and expressed in mean.
C5aR expression by quantitative reverse transcription-polymerase chain reaction
One centimeter of ileum was taken by direct snap-freezing in liquid nitrogen for 5 min and then stored at −80°C. The tissue was then homogenized in lysis buffer (from the RNA Isolation Kit; Qiagen, Valencia, Calif) for 30 s in medium speed using tissue-ruptor homogenizer. The homogenized tissue extracts were frozen at −80°C. RNA was isolated from tissue samples using the Illustra RNAspin Mini Kit (GE, Piscataway, NJ). Two micrograms of the RNA obtained was reverse transcribed using Superscript III First Strand Synthesis System (Invitrogen, Carlsbad, Calif). One hundred sixty nanograms of cDNA was used as template for reverse transcription-PCR, and the reaction was run for 40 cycles. GAPDH (part# 4352932E, GenBank NM_008085; Applied Biosystems, Foster City, Calif) was used as the internal control. The mC5aR Taqman Primer/Probe sets were purchased from Applied Biosystems (part# 00500292_s1, NM_007577). The experiments and analysis were performed using the ABI 7500SDS System (Applied Biosystems).
All data are expressed as mean ± SD. Statistical analysis was performed with one-way ANOVA using GraphPad InStat software. Significance was defined as P < 0.05.
Intestinal mucosal damage was prevented in the C5aR-deficient mice
Histological scoring of the mucosal structure was performed. Representative histological images of villi structure are shown in Figure 1A, and the percent injured villi for the four animal groups is plotted in Figure 1B. Mucosal damage in WT mice subjected to SMAO procedure was significantly greater compared with the moderate or mild mucosal damage observed in most villi structures of the C5aR KO mice, suggesting that elimination of C5aR remarkably prevented villi injury in this SMAO model.
Intestinal edema was reduced in C5aR-deficient mice
To evaluate the intestinal edema, the ratio of wet to dry weights of isolated intestinal tissue was determined. Significant intestinal edema was evident in the WT-SMAO group, whereas the edema was markedly attenuated in the C5aR KO-SMAO group (Fig. 1C). The results suggest that the elimination of C5aR reduces intestinal edema.
Intestinal neutrophil infiltration was attenuated in the C5aR-deficient mice
Neutrophil infiltration in intestinal tissue and remote organs was examined 3 h after reperfusion by two methods: by histological examination and by determination of MPO activity. The number of neutrophils per 100 villi identified by histological examination was significantly higher in the WT-SMAO group than in the C5aR KO-SMAO group (Fig. 2), and this was accompanied with a significant increase in ileal MPO activity in WT-SMAO as compared with the C5aR KO-SMAO groups (Fig. 3A). These results indicate that a significant number of neutrophils had infiltrated the intestine after 3 h of reperfusion and that elimination of C5aR greatly reduced the number of neutrophils infiltrating into the intestine.
Next, we examined whether neutrophil infiltration into remote organs had increased after 3 h of blood reperfusion by measuring lung and liver tissue MPO activity. Lung MPO activity was significantly elevated in the WT mice as compared with the C5aR KO mice subjected to SMAO (Fig. 3B). Liver MPO activity was also significantly increased in the WT-SMAO group; however, MPO activity in the liver was not significantly attenuated in C5aR KO-SMAO mice compared with WT-SMAO mice (Fig. 3C).
Apoptotic cell death in intestine was attenuated in the C5aR-deficient mice
We evaluated next if apoptotic cell death contributed to villi damage by TUNEL assay. Among the four animal groups, only the WT-SMAO group displayed significant numbers of apoptotic cells along the villi, and the other three groups displayed minimal numbers of apoptotic cells. Representative stainings of the villi structures are shown in Figure 4A. Stained cells were found mostly in epithelial and goblet (gland) cells. Multiple cross and longitudinal sections were examined for each animal, and the mean numbers of apoptotic cells per cross and longitudinal section for the four animal groups are plotted in Figure 4B. Apoptotic cell death was induced after I/R injury in both WT-SMAO and C5aR KO-SMAO and was significantly reduced in C5aR KO mice compared with WT mice.
Intestinal I/R injury induced cytokine release into circulation was prevented in C5aR-deficient mice
To evaluate if cytokines are released into plasma and involved in systematic effects, the levels of proinflammatory cytokines including TNF-α and IL-6 were determined in the plasma samples. The mean levels of plasma TNF-α and IL-6 were significantly increased in the WT mice 3 h after the reperfusion, although there was variability in response among individual animals (Fig. 5, A and B). In contrast, C5aR KO mice subjected to the same I/R procedure did not show an increase in plasma levels of TNF-α (Fig. 5A). The IL-6 level in C5aR KO mice subjected to SMAO also showed a trend of attenuation, although it was not statistically significant (Fig. 5B). Therefore, the plasma levels of TNF-α and IL-6 were elevated shortly after the intestinal I/R injury, and elimination of C5aR seemed to block this increase. The IL-1β level was also determined, and we found no statistical difference among the four groups of animals (data not shown).
Expression of C5aR was moderately increased after I/R injury
Expression of C5aR has been reported to be upregulated in a number of acute disease settings (23-25). To address if there is an alteration of C5aR expression after the intestinal I/R injury, we conducted quantitative PCR and immunostaining in the WT animals subjected to sham or SMAO to determine the expression at both mRNA and protein levels. C5aR mRNA expression level was increased in WT-SMAO compared with WT-sham by ∼75% 3 h after the reperfusion (Fig. 6). Immunostaining of the tissues collected at the same time point revealed a wide range of expression levels of C5aR protein in the WT-SMAO group. Some tissue samples from individual WT-SMAO animals showed significantly increased C5aR staining, whereas others revealed similar staining levels as compared with the WT-sham group (data not shown). Later time points need to be assessed for the expression level of C5aR protein.
Intestinal I/R after occlusion of the SMA has been used as a model to evaluate the involvement of pathways and mechanisms in I/R injury. Other studies have evaluated the role of the complement system using this model. For example, using an SMAO model, treatment with soluble CR1 attenuated the local and remote organ injury after intestinal I/R in rat (26). Furthermore, a C5aR antagonist administered before intestinal I/R injury has been shown to reduce mucosal damage. These pharmacological manipulations suggest that blocking multiple points in the complement pathway could prevent I/R injury.
In this study, we adopted a genetic model and demonstrated that C5aR deficiency reduced I/R injury. Our data suggest that elimination of C5aR (i) attenuates neutrophil infiltration in intestine, (ii) reduces MPO activity in local and remote organs, (iii) reduces intestinal edema, (iv) reduces apoptotic cell death, and (v) attenuates the elevated plasma level of proinflammatory cytokines after I/R injury.
Neutrophil infiltration has previously been suggested to mediate local tissue damage. Fleming et al. (9) have shown significant reduction in infiltrated polymorphonuclear neutrophils (PMNs) in an intestinal I/R injury model using C5−/− mice. Treatment with 1 μg of C5a did not increase neutrophil infiltration in C5−/− mice, suggesting that activation of the receptor for C5a, but not the pharmacological concentration of C5a, may be the controlling point (9). Their study, combined with our data, clearly illustrates that signaling via the C5aR pathway leads to neutrophil infiltration and that the availability and activation of the receptor for C5a are crucial in recruiting neutrophils into local organs.
The early involvement of both local and systematic proinflammatory cytokines after intestinal I/R injury has been demonstrated by various groups (27-29). Grotz et al. (20) have reported that cytokine released from the gut correlates with the magnitude of injury caused by SMAO. Recently, proinflammatory cytokines TNF-α, IL-6, and IL-1β were found to be elevated in rat plasma after intestinal I/R injury as early as 2 h after reperfusion (30). In our study using C5aR WT mice, TNF-α and IL-6 were increased in the plasma 3 h after reperfusion in the intestinal I/R injury model, which is in agreement with the results from Rocourt et al. (30). We found that variation in plasma cytokine level is large among individual animals in the same treatment group. This might imply that there are differences in the magnitude of the responses among individual animals or that 3 h may be too early to observe a consistent systematic elevation of cytokines; if so, the variation in response among individuals probably would be significantly reduced at later time points. Nonetheless, we have demonstrated for the first time in vivo that elimination of C5aR attenuates systematic TNF-α elevation. This suggests that the C5a pathway can regulate levels of proinflammatory cytokines released from intestinal neutrophils. It is likely that local cytokine levels were attenuated as well in the intestine of C5aR-deficient mice; however, further experiments are needed to confirm this hypothesis.
The effect of C5aR elimination was evaluated in both local and remote organs. It is evident that neutrophils were recruited to lungs after I/R injury, and elimination of C5aR significantly attenuated this process based on the results of MPO activity in the lungs. However, at the same time point, C5aR deficiency did not significantly block neutrophil infiltration in liver. Moreover, we measured plasma alanine aminotransferase (ALT) activity as an index for liver damage. I/R injury caused a significant elevation of plasma ALT activity 3 h after reperfusion; however, we observed that elimination of C5aR had no significant effect on plasma ALT activity (data not shown). These data suggest that involvement of C5a pathway in different remote organs varies and that the downstream signaling pathways might not be identical. Samples collected at additional time points and examination of more mediators will add to our understanding of the temporal and spatial regulation of the C5aR signaling pathway.
Epithelial apoptotic cell death has been shown to be central to cell death in I/R injury (31-33). It is evident in our study that elimination of C5aR significantly reduced the number of apoptotic cells after I/R injury. Possible mechanisms by which the C5a pathway could regulate apoptosis include both indirect and direct mechanisms (4). In the indirect mechanism, activation of the C5a pathway could regulate apoptosis by stimulating proinflammatory cytokines such as TNF-α, and other mediators such as reactive oxygen in neutrophils. Release of these mediators into the local tissues, in turn, leads to apoptosis of the epithelial cells (5). The C5a pathway could also directly act on the intestinal epithelial cells and induce apoptosis by activating the JNK and p38 signaling pathways, resulting in the activation of caspase 3, as demonstrated by previous studies (34, 35). Our studies showed a correlation between apoptotic cell death and neutrophil infiltration, thereby supporting the indirect mechanism of regulation. However, our data do not rule out the co-existence of the direct mechanism, and this awaits further investigation.
In summary, our studies support the hypothesis that the C5a pathway plays an important role in I/R injury. This pathway could have multiple effects including recruiting neutrophils to local and remote organs and inducing apoptosis in intestinal epithelial cells. Elimination of the C5aR is beneficial in reducing reperfusion-related injury and supports the potential use of C5aR antagonists as therapeutic approaches in acute clinical settings involving I/R.
The authors thank Marianne Pedersen, PhD, at Novo Nordisk for assistance in the preparation of this article.
1. de Groot H, Rauen U: Ischemia-reperfusion injury: processes in pathogenetic networks: a review. Transplant Proc
2. Collard CD, Gelman S: Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology
3. Eltzschig HK, Collard CD: Vascular ischaemia and reperfusion injury. Br Med Bull
4. Arumugam TV, Magnus T, Woodruff TM, Proctor LM, Shiels IA, Taylor SM: Complement mediators in ischemia-reperfusion injury. Clin Chim Acta
5. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM: The role of the complement system in ischemia-reperfusion injury. Shock
6. Monk PN, Scola AM, Madala P, Fairlie DP: Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol
7. Arumugam TV, Woodruff TM, Stocks SZ, Proctor LM, Pollitt S, Shiels IA, Reid RC, Fairlie DP, Taylor SM: Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol
8. de Vries B, Kohl J, Leclercq WK, Wolfs TG, van Bijnen AA, Heeringa P, Buurman WA: Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol
9. Fleming SD, Mastellos D, Karpel-Massler G, Shea-Donohue T, Lambris JD, Tsokos GC: C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury. Clin Immunol
10. Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM: Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol
11. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH: Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest
12. Fleming SD, Anderson J, Wilson F, Shea-Donohue T, Tsokos GC: C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusion. Clin Immunol
106: 55-64, 2003.
13. Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA: Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest
14. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL: Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation
15. Wada K, Montalto MC, Stahl GL: Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology
16. Wang Y, Rollins SA, Madri JA, Matis LA: Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A
17. Hopken UE, Lu B, Gerard NP, Gerard C: Impaired inflammatory responses in the reverse Arthus reaction through genetic deletion of the C5a receptor. J Exp Med
18. Hopken UE, Lu B, Gerard NP, Gerard C: The C5a chemoattractant receptor mediates mucosal defence to infection. Nature
19. Deitch EA: Animal models of sepsis and shock: a review and lessons learned. Shock
20. Grotz MR, Deitch EA, Ding J, Xu D, Huang Q, Regel G: Intestinal cytokine response after gut ischemia: role of gut barrier failure. Ann Surg
21. Deitch EA, Shi HP, Lu Q, Feketeova E, Xu DZ: Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury. Shock
22. Magnotti LJ, Upperman JS, Xu DZ, Lu Q, Deitch EA: Gut-derived mesenteric lymph but not portal blood increases endothelial cell permeability and promotes lung injury after hemorrhagic shock. Ann Surg
23. Riedemann NC, Guo RF, Neff TA, Laudes IJ, Keller KA, Sarma VJ, Markiewski MM, Mastellos D, Strey CW, Pierson CL, et al.: Increased C5a receptor expression in sepsis. J Clin Invest
24. Van BJ, Bernaudin M, Petit E, Gasque P, Nouvelot A, MacKenzie ET, Fontaine M: Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol
25. Zhang H, Qin G, Liang G, Li J, Barrington RA, Liu DX: C5aR-mediated myocardial ischemia/reperfusion injury. Biochem Biophys Res Commun
26. Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB, Moore FD Jr: Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol
27. Deitch EA, Xu D, Franko L, Ayala A, Chaudry IH: Evidence favoring the role of the gut as a cytokine-generating organ in rats subjected to hemorrhagic shock. Shock
28. Grotz M, Regel G, Schratt HE, Seekamp A, Pape HC, Tscherne H: Intestinal cytokine liberation after intestinal ischemia in the rat-studies in the Ussing chamber system. Z Gastroenterol
29. Stallion A, Kou TD, Miller KA, Dahms BB, Dudgeon DL, Levine AD: IL-10 is not protective in intestinal ischemia reperfusion injury. J Surg Res
30. Rocourt DV, Mehta VB, Besner GE: Heparin-binding EGF-like growth factor decreases inflammatory cytokine expression after intestinal ischemia/reperfusion injury. J Surg Res
31. Ikeda H, Suzuki Y, Suzuki M, Koike M, Tamura J, Tong J, Nomura M, Itoh G: Apoptosis is a major mode of cell death caused by ischaemia and ischaemia/reperfusion injury to the rat intestinal epithelium. Gut
32. Noda T, Iwakiri R, Fujimoto K, Matsuo S, Aw TY: Programmed cell death induced by ischemia-reperfusion in rat intestinal mucosa. Am J Physiol
33. Shah KA, Shurey S, Green CJ: Characterization of apoptosis in intestinal ischaemia-reperfusion injury-a light and electron microscopic study. Int J Exp Pathol
34. Giakoustidis AE, Giakoustidis DE, Koliakou K, Kaldrymidou E, Iliadis S, Antoniadis N, Kontos N, Papanikolaou V, Papageorgiou G, Atmatzidis K, et al.: Inhibition of intestinal ischemia/reperfusion induced apoptosis and necrosis via down-regulation of the NF-kB, c-Jun and caspace-3 expression by epigallocatechin-3-gallate administration. Free Radic Res
35. Murayama T, Tanabe M, Matsuda S, Shimazu M, Kamei S, Wakabayashi G, Kawachi S, Matsumoto K, Yamazaki K, Matsumoto K, et al.: JNK (c-Jun NH2
terminal kinase) and p38 during ischemia reperfusion injury in the small intestine. Transplantation
Complement pathway; knockout mice; ischemia/reperfusion injury; superior mesenteric artery occlusion; gut I/R injury